Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities
Highly potent compounds serve an increasingly significant role in numerous R&D landscapes and pharmaceutical intensive medical treatments; i.e. oncology, atrial fibrillation, osteoporosis.
FB-HRS, LLC Announces US FDA Clearance of IND Application to Initiate Clinical Trial for FBHRS001, a Treatment for Atrial Fibrillation
Atrial Fibrillation impacts a tremendous amount of people around the world and current treatment options are underwhelming due to negative side effects. FB–HRS, LLC has developed a treatment that may reduce those undesired consequences.
Frontida BioPharm and Oncoceutics Announce Product Development and Commercialization Partnership
Frontida BioPharm, Inc. and Oncoceutics Inc. announced that the two companies have entered into a product development and commercialization agreement to further develop the finished product manufacturing process for ONC201...